Midodrine Hydrochloride Strandhaven (Midodrine Hydrochloride)

Midodrine is a prodrug that is converted in the body to desglymidodrine. This active metabolite binds to peripheral alpha‑1 adrenergic receptors, causing vasoconstriction of blood vessels, which increases peripheral resistance and elevates arterial blood pressure.

The dosage of Midodrine Hydrochloride Strandhaven is individualized by the prescribing clinician based on the patient’s blood‑pressure response and tolerability. The prescriber determines the starting dose, titration schedule, and maximum daily amount.

Safety data for Midodrine Hydrochloride in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Use is only considered when the potential benefit justifies any potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative for orthostatic hypotension is fludrocortisone, a mineralocorticoid that expands plasma volume. Midodrine raises blood pressure by vasoconstriction rather than fluid retention, offering a different side‑effect profile and rapid onset, which may be preferable for patients where volume expansion is undesirable.

Midodrine Hydrochloride Strandhaven should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain potency.

The medication is taken orally, usually with a full glass of water. It is commonly administered during the day, and patients are advised to avoid taking it within four hours of lying down to reduce the risk of supine hypertension.

The most serious risks include supine hypertension, which can lead to cardiovascular events such as stroke or myocardial infarction, and severe urinary retention that may require catheterisation. Patients should be monitored closely for these complications.

Midodrine is contraindicated in patients with severe organic heart disease, uncontrolled hypertension, or a history of ischemic cardiac events. It should also be avoided in individuals with urinary retention that cannot be managed medically.